ANK-700

About Anokion

Anokion is a clinical-stage biotech pioneering a platform for antigen-specific tolerance induction to treat autoimmune diseases. Its core technology leverages the liver's natural immune tolerance pathways to re-educate the immune system to ignore specific self-antigens, offering a potentially curative and safer alternative to broad immunosuppressants. The company is advancing a pipeline of programs for celiac disease and multiple sclerosis, backed by experienced leadership and venture capital investors. As a private entity, its success hinges on clinical validation, platform expansion, and future strategic partnerships or financing.

Therapeutic Areas

Other Celiac Disease Drugs